Patient details
Case no. . | Age, y . | Sex . | Isotype . | Disease status . | Cyclin D class immunohistochemistry and/or WB . | FISH . | Source of cells . |
---|---|---|---|---|---|---|---|
1 | 46 | Female | IgG λ | De novo* | Cyclin D2 | t(14;16) | BM |
2 | 69 | Female | IgG λ | De novo | Cyclin D2 | t(4;14) | BM |
3 | 58 | Male | IgG λ | 1st relapse* | Cyclin D2 | t(14;16) | BM |
4 | 41 | Female | IgG λ | 2nd relapse* | Cyclin D2 | 17pdel | PB |
5 | 69 | Male | IgA κ | 2nd relapse* | Cyclin D2 | 17pdel | BM |
6 | 58 | Female | IgG λ | 2nd relapse* | Cyclin D2 | t(14;16) | PB |
7 | 59 | Male | IgA κ | 2nd relapse | Cyclin D2 | t(4;14) | BM |
8 | 68 | Male | IgG κ | 3rd relapse | Cyclin D2 | 17pdel | BM |
9 | 60 | Female | κ LC | De novo | Cyclin D2 | Nil | BM |
10 | 58 | Female | IgG λ | De novo | Cyclin D2 | Nil | BM |
11 | 73 | Male | λ LC | 2nd relapse* | Cyclin D2 | t(14;16) | PB |
12 | 54 | Male | IgA λ | 1st relapse* | Cyclin D2 | 17pdel | BM |
13 | 71 | Female | λ LC | De novo* | Cyclin D2 | t(14;16) | BM |
14 | 55 | Female | IgA λ | 2nd relapse | Cyclin D2 | t(4;14) | BM |
15 | 57 | Female | IgG λ | 3rd relapse | Cyclin D2 | Nil | BM |
16 | 48 | Male | λ LC | 1st relapse | Cyclin D1 | t(11;14) | BM |
17 | 74 | Male | IgG λ | 3rd relapse | Cyclin D1 | Nil | BM |
18 | 58 | Male | IgG κ | 1st relapse | Cyclin D1 | Nil | BM |
19 | 68 | Male | IgG λ | 2nd relapse | Cyclin D1 | Nil | BM |
20 | 62 | Male | IgG κ | 2nd relapse | Cyclin D1 | t(11;14) | BM |
21 | 44 | Male | IgG κ | 1st relapse | Cyclin D1 | t(11;14) | BM |
22 | 61 | Male | IgA κ | 1st relapse | Cyclin D1 | 17pdel | BM |
23 | 67 | Male | IgG κ | 2nd relapse | Cyclin D1 | t(11;14) | BM |
24 | 48 | Male | IgG κ | 1st relapse | Cyclin D1 | Nil | BM |
25 | 57 | Male | IgG κ | 2nd relapse | Cyclin D1 | Nil | BM |
26 | 72 | Female | IgG κ | 2nd relapse | Cyclin D1 | Nil | BM |
27 | 69 | Male | κ LC | 1st relapse | Cyclin D1 | 17pdel | BM |
28 | 78 | Male | IgG κ | 3rd relapse | Cyclin D1 | Nil | BM |
29 | 58 | Male | IgG κ | 1st relapse | Cyclin D1 | Nil | BM |
30 | 56 | Male | IgG λ | 2nd relapse* | Cyclin D1 | t(11;14) | BM |
31 | 60 | Female | IgA λ | 2nd relapse | Cyclin D1 | t(11;14) | BM |
32 | 66 | Female | IgG λ | De novo* | Cyclin D1 | t(11;14) | BM |
33 | 87 | Male | IgG κ | 1st relapse | Cyclin D1 | t(11;14) | BM |
34 | 68 | Male | IgA λ | 4th relapse | Cyclin D1 | t(11;14) | BM |
Case no. . | Age, y . | Sex . | Isotype . | Disease status . | Cyclin D class immunohistochemistry and/or WB . | FISH . | Source of cells . |
---|---|---|---|---|---|---|---|
1 | 46 | Female | IgG λ | De novo* | Cyclin D2 | t(14;16) | BM |
2 | 69 | Female | IgG λ | De novo | Cyclin D2 | t(4;14) | BM |
3 | 58 | Male | IgG λ | 1st relapse* | Cyclin D2 | t(14;16) | BM |
4 | 41 | Female | IgG λ | 2nd relapse* | Cyclin D2 | 17pdel | PB |
5 | 69 | Male | IgA κ | 2nd relapse* | Cyclin D2 | 17pdel | BM |
6 | 58 | Female | IgG λ | 2nd relapse* | Cyclin D2 | t(14;16) | PB |
7 | 59 | Male | IgA κ | 2nd relapse | Cyclin D2 | t(4;14) | BM |
8 | 68 | Male | IgG κ | 3rd relapse | Cyclin D2 | 17pdel | BM |
9 | 60 | Female | κ LC | De novo | Cyclin D2 | Nil | BM |
10 | 58 | Female | IgG λ | De novo | Cyclin D2 | Nil | BM |
11 | 73 | Male | λ LC | 2nd relapse* | Cyclin D2 | t(14;16) | PB |
12 | 54 | Male | IgA λ | 1st relapse* | Cyclin D2 | 17pdel | BM |
13 | 71 | Female | λ LC | De novo* | Cyclin D2 | t(14;16) | BM |
14 | 55 | Female | IgA λ | 2nd relapse | Cyclin D2 | t(4;14) | BM |
15 | 57 | Female | IgG λ | 3rd relapse | Cyclin D2 | Nil | BM |
16 | 48 | Male | λ LC | 1st relapse | Cyclin D1 | t(11;14) | BM |
17 | 74 | Male | IgG λ | 3rd relapse | Cyclin D1 | Nil | BM |
18 | 58 | Male | IgG κ | 1st relapse | Cyclin D1 | Nil | BM |
19 | 68 | Male | IgG λ | 2nd relapse | Cyclin D1 | Nil | BM |
20 | 62 | Male | IgG κ | 2nd relapse | Cyclin D1 | t(11;14) | BM |
21 | 44 | Male | IgG κ | 1st relapse | Cyclin D1 | t(11;14) | BM |
22 | 61 | Male | IgA κ | 1st relapse | Cyclin D1 | 17pdel | BM |
23 | 67 | Male | IgG κ | 2nd relapse | Cyclin D1 | t(11;14) | BM |
24 | 48 | Male | IgG κ | 1st relapse | Cyclin D1 | Nil | BM |
25 | 57 | Male | IgG κ | 2nd relapse | Cyclin D1 | Nil | BM |
26 | 72 | Female | IgG κ | 2nd relapse | Cyclin D1 | Nil | BM |
27 | 69 | Male | κ LC | 1st relapse | Cyclin D1 | 17pdel | BM |
28 | 78 | Male | IgG κ | 3rd relapse | Cyclin D1 | Nil | BM |
29 | 58 | Male | IgG κ | 1st relapse | Cyclin D1 | Nil | BM |
30 | 56 | Male | IgG λ | 2nd relapse* | Cyclin D1 | t(11;14) | BM |
31 | 60 | Female | IgA λ | 2nd relapse | Cyclin D1 | t(11;14) | BM |
32 | 66 | Female | IgG λ | De novo* | Cyclin D1 | t(11;14) | BM |
33 | 87 | Male | IgG κ | 1st relapse | Cyclin D1 | t(11;14) | BM |
34 | 68 | Male | IgA λ | 4th relapse | Cyclin D1 | t(11;14) | BM |
LC indicates light chain; Nil, no IgH/TC; BM, bone marrow; and PB, peripheral blood.
Patient who had circulating plasma cells.